Not yet recruitingPHASE1, PHASE2NCT05559801

Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)

Studying Osteogenesis imperfecta

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Emory University
Principal Investigator
Doris Fadoju, MD, MD
Emory University
Intervention
Bone marrow-derived mesenchymal stromal cells (MSCs)(drug)
Enrollment
12 enrolled
Eligibility
3-10 years · All sexes
Timeline
20262026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05559801 on ClinicalTrials.gov

Other trials for Osteogenesis imperfecta

Additional recruiting or active studies for the same condition.

See all trials for Osteogenesis imperfecta

← Back to all trials